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Objectives: To determine (1) the effects of weight loss in obese subjects on six adipokines and joint
biomarkers; and (2) the relationship between changes in these markers with changes in cartilage
outcomes.
Design: Plasma levels of adiponectin, leptin, IL-6, COMP, MMP-3 and urine levels of CTX-II were
measured at baseline and 12 months from 75 obese subjects enrolled in two weight-loss programs.
Magnetic resonance imaging (MRI) was used to assess cartilage volume and thickness. Associations
between weight loss, cartilage outcomes and markers were adjusted for age, gender, baseline BMI,
presence of clinical knee OA, with and without weight loss percent.
Results: Mean weight loss was 13.0 ± 9.5%. Greater weight loss percentage was associated with an in-
crease in adiponectin (b ¼ 0.019, 95% CI 0.012 to 0.026,) and a decrease in leptin (b ¼ 1.09, 95% CI 1.37
to 0.82). Multiple regression analysis saw an increase in adiponectin associated with reduced loss of
medial tibial cartilage volume (b ¼ 14.4, CI 2.6 to 26.3) and medial femoral cartilage volume (b ¼ 18.1, 95%
CI 4.4 to 31.8). Decrease in leptin was associated with reduced loss of medial femoral volume (b ¼ 4.1,
95% CI 6.8 to 1.4) and lateral femoral volume (b ¼ 1.8, 95% CI 3.7 to 0.0). When weight loss percent
was included in the model, only the relationships between COMP and cartilage volume remained sta-
tistically signiﬁcant.
Conclusions: Adiponectin and leptin may be associated with cartilage loss. Further work will determine
the relative contributions of metabolic and mechanical factors in the obesity-related joint changes.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA), is the clinical syndrome of joint pain and
dysfunction caused by joint degeneration1, and of the weight-
bearing joints, the knee is most frequently involved2. Obesity is a
signiﬁcant risk factor for both the incidence and progression of
knee OA3e5. The mechanisms by which obesity contributes to knee
joint structural damage are thought to be secondary to bothto: A. Anandacoomarasmy,
, Concord General Hospital,
831; Fax: 61-2-9767-5421.
.K. King), holger.henneicke@
ey.edu.au (M.J. Seibel), lyn.
d.usyd.edu.au, ana.ananda@
ternational. Published by Elsevier Lmechanical and metabolic factors6, as being obese also increases
the risk of OA in non-weight-bearing joints such as the hands7. The
precise metabolic pathways through which obesity contributes to
knee joint structural damage are currently not known, although
thought to involve aberrant adipokine expression with direct and
downstream effects leading to the destruction and remodeling of
joint tissue8,9.
White adipose tissue is now known to be an abundant source
of mediators involved in many disease processes10. Adipokines
exert modulatory actions on target tissues and cells involved in
OA, including cartilage, synovium and bone. Leptin and adipo-
nectin are the most abundantly produced adipokines11 and their
receptors are expressed on the surface of chondrocytes, syno-
viocytes and subchondral osteoblasts12e14. Histologically assessed
depletion of proteoglycan in articular cartilage was observed after
leptin was injected into the knee joint of rats15. Leptin maytd. All rights reserved.
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through induction of matrix metalloproteinases (MMPs), nitric
oxide and production of pro-inﬂammatory cytokines12,16e18.
Levels of adipokines in obese people may be particularly impor-
tant, as obesity may produce a biochemical environment in which
chondrocytes cannot respond to such challenges; chondrocytes
from obese OA patients have been shown to exhibit a response
pattern to leptin different from normal or overweight patients19.
Less is known about the role of adiponectin in joint disease, with
both pro-inﬂammatory and anti-inﬂammatory properties being
reported locally8,20,21, compared to its systemic anti-inﬂammatory
effects11. Levels of leptin and adiponectin are signiﬁcantly
elevated in people with OA compared to controls22. A recent study
of obese subjects with knee OA demonstrated decreased circulating
levels of leptin and increased circulating levels of adiponectin after
weight loss23, raising the question of the effects of adipokines on
OA disease progression.
Biomarkers offer a promising new approach for early diagnosis
and monitoring the progression of OA. As loss of articular cartilage
is a hallmark of the disease, biomarkers of cartilage degradation
have received the most attention. Serum cartilage oligomeric ma-
trix protein (COMP) and urine c-telopeptide of type II collagen
(CTX-II) are both markers of cartilage degradation according to the
“BIPED” classiﬁcation24, and have had the best performance of all
currently available commercial biomarkers25. Levels of both have
been correlated with cartilage defects on magnetic resonance im-
aging (MRI) in cross-sectional studies26e28, although correlation
between change in thesemarkers over time and cartilage outcomes
are not well established28,29. Biomarkers of bone and synovial
turnover have also been studied, with less promising results so
far25. Other studies have investigated MMPs, which are molecules
produced from chondrocytes that attack aggrecan, ﬁbronectin and
type II collagen. In particular, MMP-3 is elevated in the blood of
patients with knee OA30, and reduction over time has been corre-
lated with reduction in cartilage volume loss31.
Weight loss in obese subjects has been shown to reduce
symptoms of knee OA and reduce future progression of the disease.
Recently it was demonstrated that obese people who lose weight
have reduced cartilage loss32. Previous studies have found a
decrease in COMP serum concentrations in obese subjects who lose
weight through bariatric surgery23 or diet and exercise in-
terventions33; however, these studies did not ﬁnd any relationship
between COMP and adipokine changes, and did not assess cartilage
loss.
Our aim was to investigate the effect of weight loss on adipo-
kines and joint biomarkers in obese subjects with and without
clinical knee OA, and to measure for the ﬁrst time the association
between changes in level of markers and changes in cartilage
outcomes on MRI in this population.
Method
Participants
Details of this cohort were previously reported in Refs. 32,34.
One hundred and eleven patients were prospectively recruited
from two weight loss programs (non-surgical and surgical) at
two urban tertiary referral hospitals, public and private, respec-
tively. All subjects were obese with the majority being obesity
grade II or higher. The non-surgical program involved dietary
modiﬁcation and exercise, and the surgical group underwent
laparoscopic adjustable banding; all subjects had self-enrolled.
Exclusion criteria included inﬂammatory arthritis. Seventy-
eight subjects completed MRI follow-up for cartilage assess-
ment at 12 months, of whom 75 subjects had sufﬁcient volume ofstored plasma and urine samples for adipokine and joint
biomarker analysis.
Assessments
Subjects were assessed at recruitment (baseline, prior to start of
weight-loss program) and again 12 months later.
Clinical assessment
Weight loss, weight loss percent, waistehip ratio and BMI were
assessed. The diagnosis of knee OAwas based on the clinical criteria
described by Altman et al.35.
Cartilage measurements
Subjects underwent baseline MRI of the symptomatic or
dominant asymptomatic knee. Sagittal MRI images were obtained
on a 3T scanner (Magnetom Trio; Siemens, Erlangen, Germany) as
previously described in Ref. 34. Cartilage volume and thickness
were measured by a single trained reader by performing cartilage
segmentation (weight-bearing femoral cartilage and all of the tibial
cartilage) using propriety software (Chondrometrics, Ainring, Ger-
many), which has been shown to be both reliable and valid36. The
reader (AA) was blinded to all clinical data. The change in both knee
cartilage volume and thickness over 12 months was calculated for
the medial tibial, medial femoral, lateral tibial and lateral femoral
compartments by subtracting the follow-up value from the base-
line value. The intraclass correlation (ICC) was >0.91 for each region
of interest.
Biochemical assays
Venous blood and urine were collected at baseline and 12
months in the non-fasted state. The blood was centrifuged to
separate plasma, and then the specimens were aliquoted into 1 ml
cryotubes. Plasma and urine were stored at 80C until analyzed.
Plasma levels of leptin, adiponectin, interleukin-6 (IL-6), COMP and
MMP-3 and urine concentrations of CTX-II were assessed for each
sample and time point.
All markers were determined using speciﬁc assay kits in
accordance with manufacturers' instructions. Quantikine Human
ELISA kits (R&D systems, Inc., Minneapolis, Minnesota, USA) were
used for the determination of adiponectin (sensitivity 0.25 ng/ml,
intra- and inter-assay coefﬁcient of variation (CVs) 6.5% and 3.5%,
respectively), leptin (sensitivity 7.8 pg/mL, and intra- and inter-
assay CVs 4.4% and 3.2%), respectively, IL-6 (sensitivity 0.7 pg/
ml, and intra- and inter-assay CVs 2.7% and 3.1 %, respectively),
COMP (sensitivity 0.01 ng/ml, and intra- and inter-assay CVs are
4.6% and 3.2%, respectively) and MMP-3 (sensitivity 0.009 ng/mL,
and intra- and inter-assay CVs 7.8% and 6.1%, respectively). The
Urine Cartilaps ELISA (IDS, Boldon, United Kingdom) was used for
determination of CTX-II (sensitivity 0.20 ng/mL, intra- and inter-
assay CVs 4.6% and 8.1%, respectively). Urinary creatinine was
measured by a routine chemistry method and used for calculation
of creatinine-corrected urinary CTX-II concentrations. Corrected
CTX-II value (mg/mmol) was calculated as CartiLaps CTX-II (mg/L)/
creatinine (mmol/L).
All samples were measured in duplicate for each marker. The
average of the two values was reported and used in data analyses.
Duplicate samples that did not provide a CV of <15% as well as
sample readings outside of the published assay range were dis-
regarded from the analysis.
Statistical analysis
Descriptive statistics were performed and reported as mean
(SD). Paired t-test and Wilcoxon matched-pair signed-rank test
Table II
Levels of adipokines and biomarkers at baseline and 12 months
Baseline 12 Months P* value
No. Median
(interquartile
range)/mean (SD)
No. Median
(interquartile
range)/mean (SD)
Adiponectin,
mg/ml
72 4.8 (3.0e6.4) 74 6.6 (4.1e9.9) <0.001
Leptin, ng/ml 74 44.8 (20.0) 74 41.1 (24.4) 0.03
IL-6, pg/ml 50 2.6 (1.7e4.3) 70 3.8 (2.6e5.5) <0.001
COMP, ng/ml 74 233 (167e327) 74 203 (149e299) 0.009
MMP-3, ng/ml 74 5.7 (3.9e10.0) 74 5.1 (3.6e8.8) 0.12
uCTX-II,
mg/mmol
71 268 (173e359) 64 308 (175e463) 0.20
*Wilcoxon marched-pair signed-rank test or Paired t-test where appropriate.
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at baseline and 12 months. Logarithmic transformation was per-
formed for adiponectin, IL-6, OCMP, MMP-3 and CTX-II as values
did not follow a normal distribution. Spearman correlation anal-
ysis was used to analyze the association between change in each
marker and percentage weight loss, as well as with changes in
cartilage volume. The ManneWhitney test was used for categor-
ical variables. Linear regression was used to examine the associ-
ations between percentage weight loss and markers, as well as
markers and cartilage outcomes. Multiple regression analyses
were used to estimate parameters, and were adjusted for age,
gender, baseline BMI, presence of clinical knee OA and weight loss
percent as these parameters have previously been shown to be
associated with change in cartilage parameters. All statistical
analyses were performed using SPSS standard version 19.0 (SPSS,
Chicago, Illinois, USA). A P value <0.05 was considered statistically
signiﬁcant for all comparisons. Beta (b) was used designate the
standardized co-efﬁcients derived from the multiple regression
models.Results
Demographic characteristics of patients
Our study population consisted of 75 obese subjects. Charac-
teristics of this cohort are presented in Table I. Mean weight loss
percent at 12 months was 13.0 ± 9.5%. The percentage of subjects
who achieved any weight loss at 12 months was 80%. The group
that underwent surgery for weight loss achieved greater percent-
age body weight loss than the non-surgical group (17.0 ± 7.4% and
3.1 ± 6.6%, respectively).
Mean cartilage volume loss over 12 months was
45.9 ± 149 mm3, 44.1 ± 173 mm3, 61.9 ± 189 mm3 and
67.3 ± 114 mm3 for the medial tibial (MT), medial lateral (MF),
lateral tibial (LT) and lateral femoral (LF) compartments, respec-
tively. Mean cartilage thickness loss over 12 months was
0.017 ± 0.127 mm, 0.007 ± 0.223 mm, 0.003 ± 0.140 mm and
0.061 ± 0.174 mm for the MT, MF, LT and LF compartments,
respectively.Effect of time and weight loss on adipokines and joint biomarkers
The levels of adipokines and biomarkers at baseline and 12
months are shown in Table II. As expected, mean levels of adipo-
nectin increased (P < 0.001) and mean levels of leptin decreased
(P ¼ 0.03). IL-6 was found to increase in our subjects (P < 0.001).
Furthermore, we observed a decrease in COMP (P ¼ 0.009) over 12
months but there was no statistically signiﬁcant change in plasma
concentrations of MMP-3 or urine CTX-II.
The association between weight change and adipokines and
biomarkers are presented in Table III. Greater weight loss wasTable I
Characteristics of obese cohort
Characteristic Baseline 12 months P value
Age, yrs ± SD (range) 52 ± 12 (26e77) NA NA
Females, n (%) 52 (69.3) NA NA
Clinical knee OA, n (%) 23 (30.7%) NA NA
Surgical patients, n (%) 26 (34.6%) NA NA
BMI, kg/m2 ± SD 39.9 ± 5.1 36.6 ± 5.8 <0.001
Weight, kg ± SD 111.8 ± 8.9 102.5 ± 18.3 <0.001
Waist, cm ± SD 119.0 ± 13.0 113.5 ± 14.7 <0.001
WaisteHip ratio ± SD 0.92 ± 0.09 0.91 ± 0.08 <0.001
OA, osteoarthritis; BMI, body mass index.associated with a statistically signiﬁcant increase in adiponectin,
and a statistically signiﬁcant decrease in leptin (Fig. 1). It was also
associated with a statistically signiﬁcant decrease in COMP, but
there was no statistically signiﬁcant association with changes in IL-
6, MMP-3 or CTX-II concentrations.
Effect of other variables on adipokines and joint biomarkers
There was no statistically signiﬁcant effect of age, gender
or clinical knee OA on changes in adipokines and/or joint
biomarkers.
Effect of levels of adipokines and biomarkers on cartilage outcomes
Cartilage outcomes are presented in Table IV.
For cartilage volume, inmultiple regression analysis adjusted for
age, baseline BMI, gender and clinical knee OA, an increase in adi-
ponectin was associated with reduced loss of MT cartilage volume
(P ¼ 0.02) and MF cartilage volume (P ¼ 0.01). A decrease in leptin
was associated with reduced loss of MF (P ¼ 0.004) and LF cartilage
volume (P ¼ 0.05). A decrease in COMP was associated with
reduced loss of MT (P ¼ 0.007) and LT cartilage volume (P ¼ 0.03).
Whenweight-loss percent was added to the model, the association
between reduced COMP and reduced MT and LT volume loss
remained statistically signiﬁcant.
For cartilage thickness, in multiple regression analysis adjusted
for age, baseline BMI, gender and clinical knee OA, an increase in
adiponectin was associated with reduced loss in MT thickness
(P ¼ 0.03). A decrease in leptin was associated with reduced MF
cartilage thickness loss (P ¼ 0.02) and a decrease in COMP was
associated with reduced MT cartilage thickness loss (P ¼ 0.007).
When weight loss percent was included in the model the associa-
tion between reduced COMP and reduced MT cartilage loss
remained statistically signiﬁcant (P ¼ 0.01).
In multiple regression analysis adjusted for age, baseline BMI,
gender and clinical knee OA, baseline or change in leptin-to-
adiponectin ratio was not associated with either baseline or
change in any of the MRI cartilage outcomes, respectively.
There was no statistically signiﬁcant association observed be-
tween changes in adipokines and joint biomarkers with changes in
lateral cartilage volume or thickness. Baseline levels of adipokines
and joint biomarkers were not prognostic of cartilage changes over
the 12 months study period. Waist/hip ratio did not affect cartilage
parameters.
Discussion
This study provides evidence that appropriate plasma levels of
adiponectin and leptin may be associated with a preservation of
Table III
Associations between weight change and adipokines and biomarkers at 12 months
Regression models Coefﬁcient* (95% CI) P value Coefﬁcienty (95% CI) P value
Dependent variable Independent variable
Adiponectin Weight loss (%) 0.019 (0.012, 0.026) <0.001 0.019 (0.011, 0.026) <0.001
Weight loss (kg) 0.014 (0.008, 0.020) <0.001 0.015 (0.009, 0.021) <0.001
Leptin Weight loss (%) 1.09 (1.37, 0.82) <0.001 1.13 (1.41, 0.84) <0.001
Weight loss (kg) 0.83 (1.06, 0.61) <0.001 0.87 (1.11, 0.63) <0.001
IL-6 Weight loss (%) 0.001 (0.024, 0.006) 0.23 0.013 (0.028, 0.003) 0.10
Weight loss (kg) 0.005 (0.016, 0.007) 0.42 0.009 (0.021, 0.003) 0.15
COMP Weight loss (%) 0.009 (0.015, 0.002) 0.01 0.009 (0.016, 0.002) 0.01
Weight loss (kg) 0.007 (0.012, 0.001) 0.01 0.007 (0.013, 0.002) 0.01
MMP-3 Weight loss (%) 0.003 (0.012, 0.005) 0.40 0.004 (0.012, 0.004) 0.29
Weight loss (kg) 0.002 (0.008, 0.005) 0.63 0.004 (0.010, 0.003) 0.23
uCTX-II Weight loss (%) 0.004 (0.013, 0.021) 0.66 0.002 (0.016, 0.019) 0.84
Weight loss (kg) 0.004 (0.010, 0.018) 0.59 0.002 (0.013, 0.016) 0.80
* Adjusted for baseline value.
y Adjusted for baseline value, age at baseline, gender, baseline BMI and presence of clinical knee OA.
L.K. King et al. / Osteoarthritis and Cartilage 23 (2015) 397e404400cartilage in (obese) patients with and without knee OA. Obese pa-
tients who lost a moderate percentage of their body weight (13%)
displayed statistically signiﬁcantly change in the levels of these
circulating adipokines, and these biochemical changes were asso-
ciated with a reduction in cartilage loss assessed byMRI. This effect
may be one of the ways that obesity inﬂuences radiological out-
comes, although these results suggest that mechanical loading may
be the dominant etiology. To our knowledge, there have been no
previous studies investigating the effect of weight loss on re-
lationships between adipokines, joint biomarkers and cartilage
outcomes on MRI in people with obesity.
In our study, weight loss resulted in a statistically signiﬁcant
increase in adiponectin and decrease in leptin and COMP plasmaFig. 1. Association between weight loconcentrations, similar to results observed in previous trials23,33.
A recent study by Richette et al. found that in a cohort of patients
with obesity and knee OA, surgically induced weight loss (mean:
20%) resulted in a signiﬁcant increase in adiponectin, decrease in
leptin and decrease in COMP, but no relationships between adi-
pokines and joint biomarkers were found23. In contrast, in this
study we observed a statically signiﬁcant association between
reduction in leptin and reduction in COMP plasma concentrations,
independent of weight loss percentage. However, the association
between leptin and cartilage loss did not reach statistical signiﬁ-
cance when weight loss percent was controlled for; this likely
reﬂects the strong correlation betweenweight loss and changes in
leptin as well as the importance of the beneﬁts to articularss (%) and change in adipokines.
Table IV
Associations between changes in adipokines and biomarkers and cartilage outcomes at 12 months
Regression models: Coefﬁcient* (95% CI) P value Coefﬁcienty (95% CI) P value
Dependent variable Independent variable
MT volume Adiponectin 14.4 (2.6, 26.3) 0.02 11.1 (2.5, 24.7) 0.11
Leptin 2.0 (4.5, 0.5) 0.11 0.7 (3.9, 2.5) 0.67
IL-6 12.1 (8.2, 32.4) 0.24 12.8 (7.7, 33.3) 0.21
COMPz 7.1 (12.2, 2.1) 0.007 6.2 (11.4, 1.0) 0.02
MMP-3 10.2 (27.5, 7.0) 0.24 9.5 (26.4, 7.4) 0.26
uCTX-IIx 1.0 (3.0, 0.9) 0.30 0.9 (2.8, 1.1) 0.37
MF volume Adiponectin 18.1 (4.4, 31.8) 0.01 7.1 (7.7, 21.9) 0.34
Leptin 4.1 (6.8, 1.4) 0.004 1.3 (4.7, 2.1) 0.45
IL-6 5.9 (26.1, 14.3) 0.56 3.7 (23.7, 16.2) 0.71
COMPz 5.4 (11.4, 0.7) 0.08 2.5 (8.3, 3.3) 0.39
MMP-3 6.5 (26.4, 13.4) 0.52 4.5 (22.5, 13.5) 0.62
uCTX-IIx 0.4 (2.7, 1.9) 0.72 0.0 (2.1, 2.1) 1.00
LT volume Adiponectin 2.6 (20.7, 15.6) 0.78 7.5 (27.5, 12.5) 0.45
Leptin 0.5 (4.0, 2.9) 0.75 0.9 (3.8, 5.5) 0.71
IL-6 10.2 (10.8, 31.1) 0.33 12.0 (9.8, 33.7) 0.27
COMPz 7.3 (14.1, 0.6) 0.03 7.0 (13.9, 0.2) 0.04
MMP-3 7.7 (29.6, 14.3) 0.49 7.1 (29.2, 14.9) 0.52
uCTX-IIx 0.4 (2.8, 2.1) 0.77 0.2 (2.7, 2.2) 0.86
LF volume Adiponectin 0.6 (7.9, 9.1) 0.89 4.5 (14.4, 5.5) 0.38
Leptin 1.8 (3.7, 0.0) 0.05 1.5 (3.9, 0.9) 0.22
IL-6 4.5 (19.5, 10.5) 0.55 2.4 (17.5, 12.7) 0.75
COMPz 2.6 (6.5, 1.2) 0.18 2.2 (6.1, 1.7) 0.27
MMP-3 6.0 (18.6, 6.6) 0.34 5.2 (17.7, 7.4) 0.41
uCTX-IIx 0.6 (2.0, 0.8) 0.39 0.5 (1.9, 0.9) 0.49
MT thickness Adiponectin 0.011 (0.001, 0.022) 0.03 0.010 (0.002, 0.022) 0.10
Leptin 0.001 (0.003, 0.001) 0.45 0.000 (0.003, 0.003) 0.86
IL-6 0.008 (0.011, 0.027) 0.40 0.009 (0.010, 0.028) 0.36
COMPz 0.006 (0.011, 0.002) 0.007 0.006 (0.010, 0.001) 0.01
MMP-3 0.003 (0.018, 0.012) 0.65 0.003 (0.018, 0.012) 0.69
uCTX-IIx 0.001 (0.002, 0.001) 0.46 0.001 (0.002, 0.001) 0.55
MF thickness Adiponectin 0.017 (0.001, 0.035) 0.06 0.007 (0.012, 0.027) 0.46
Leptin 0.004 (0.008, 0.001) 0.02 0.002 (0.006, 0.003) 0.44
IL-6 0.016 (0.042. 0.011) 0.24 0.014 (0.041, 0.012) 0.28
COMPz 0.003 (0.011, 0.004) 0.38 0.001 (0.009, 0.007) 0.81
MMP-3 0.006 (0.031, 0.020) 0.66 0.004 (0.028, 0.020) 0.76
uCTX-IIx 0.001 (0.004, 0.002) 0.65 0.000 (0.003, 0.002) 0.82
LT thickness Adiponectin 0.004 (0.018, 0.009) 0.52 0.006 (0.021, 0.009) 0.44
Leptin 0.000 (0.003, 0.002) 0.74 0.001 (0.004, 0.003) 0.75
IL-6 0.004 (0.018, 0.010) 0.59 0.004 (0.019, 0.011) 0.58
COMPz 0.003 (0.009, 0.002) 0.20 0.003 (0.009, 0.002) 0.21
MMP-3 0.002 (0.019, 0.014) 0.80 0.002 (0.019, 0.015) 0.80
uCTX-IIx 0.001 (0.001, 0.002) 0.50 0.001 (0.001, 0.002) 0.51
LF thickness Adiponectin 0.002 (0.016, 0.011) 0.74 0.003 (0.020, 0.013) 0.69
Leptin 0.002 (0.005, 0.001) 0.26 0.003 (0.007, 0.001) 0.13
IL-6 0.009 (0.033, 0.015) 0.45 0.009 (0.033, 0.016) 0.48
COMPz 0.001 (0.007, 0.006) 0.81 0.001 (0.007, 0.006) 0.80
MMP-3 0.002 (0.021, 0.018) 0.88 0.002 (0.022, 0.019) 0.88
uCTX-IIx 0.001 (0.003, 0.002) 0.57 0.001 (0.003, 0.002) 0.58
* Adjusted for baseline value, age at baseline, gender, baseline BMI and presence of clinical knee OA.
y Adjusted for baseline value, age at baseline, gender, baseline BMI, presence of clinical knee OA and weight loss percentage.
z Every 10 ng/ml.
x Every 10 mg/mmol.
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ciated with weight loss.
There has been a growing interest in the correlation of OA bio-
markers with cartilage outcomes, but to date most evidence is
derived from cross-sectional or longitudinal studies with radio-
graphic outcomes rather than MRI. This study therefore provides
evidence that changes in circulating adipokines are not only asso-
ciated with changes in joint biomarkers (here COMP) but may be
associated with a preservation of knee cartilage as determined by
MRI. Furthermore, we found reduced loss of cartilage was associ-
ated with reduction in plasma levels of COMP, adding to the pool of
evidence that COMP is a promising biomarker for OA. In accordancewith our ﬁndings, Berry et al. reported that in a group of subjects
with knee OA followed for 2 years, changes in levels of COMP
correlated with medial cartilage volume loss in subjects with
lower-than-average COMP levels29. In a recent study by Erhart-
Hledik et al., changes in serum COMP observed after a 30-min
walk were correlated with cartilage thickness in the medial fe-
mur and tibia over a 5-year period indicating that the mechanical
stimulus could better delineate cartilage undergoing increased
degradation37.
Studies that have investigated the effect of weight loss on OA
biomarkers are scarce and have not studied a general obese pop-
ulation but rather focused on subjects with established, generally
L.K. King et al. / Osteoarthritis and Cartilage 23 (2015) 397e404402severe, OA23,33. This is a marked difference to the present study, in
which subjects were recruited from two weight loss programs and
only 30% were found to have clinical evidence of OA at baseline. We
found no change in MMP-3 or urine CTX-II with moderate weight
loss, and no relationship between these markers and cartilage
outcomes. Bruyere et al. found that an increase in CTX-II after 3
months was signiﬁcantly correlated with low cartilage thickness at
1 year in a cohort of subjects with established disease28. Some
authors have suggested that urine CTX-II measurementsmay not be
suitable to detect subtle changes of cartilage metabolism in a single
joint indicative of early OA, as uCTX-II release from articular carti-
lage has to be sufﬁciently elevated to bio-concentrate in urine, a
state more resembling an established OA pathology38. Similarly,
while MMP-3 has been shown to be elevated in patients with knee
OA and predict radiographic progression30, it may be that MMP-3
was not sufﬁciently elevated in our cohort to produce detectable
change in levels in early disease. Additionally, the short follow-up
time may have limited the observation of changes.
Obesity is characterized by a low-grade inﬂammatory state,
leading to its effects on many organ systems. Previous studies have
found that weight loss is associated with a decrease in circulating
markers of inﬂammation, such as CRP, TNF and IL-623,39e41. We
were surprised not to ﬁnd this association betweenweight loss and
IL-6. In the present study we did not observe an association be-
tween baseline levels of IL-6 and the presence of clinical knee OA,
or change in IL-6 and cartilage outcomes; as previously reported
associations have been with X-ray changes42,43. Recent work has
suggested the infra-patellar fat pad may be a more important
source of locally active IL-644 affecting the knee joint rather than
the systemic levels measured in our study.
While a recent study by Hunter et al. with similar numbers of
patients45, did not observe an association between weight loss and
cartilage changes on MRI, the authors found a trend towards im-
provements in bone marrow lesions (BMLs). Given the association
with BMLs and pain46, this may be of particular clinical relevance.
The sequences to assess BMLs could not be incorporated into our
study protocol due to image acquisition restrictions. In this cohort
there was no association between adipokines or joint biomarkers
and cartilage loss in the lateral compartment, consistent with
previous studies29. While a systemic process would be expected to
affect all compartments of the knee equally, interactions between
mechanical and metabolic processes could explain why we
observed more effects in the medial compartment. In most subjects
in this cohort we found varus alignment, wheremechanical loading
disproportionally affects the medial compartment of the knee.
This was a prospective cohort study involving a heterogeneous
sample of obese subjects, with subjects recruited from both non-
surgical and surgical centers. These data have generated hypothe-
ses that serve as a basis for further study. MRI imaging at the knee
has also allowed us to measure cartilage volume and thickness in a
more reliable way. Our study has some limitations. This is a het-
erogeneous group of patients and the presence of radiological OA
could not be accounted for as radiographs were not performed. It
would be useful to explore among larger cohort studies whether
the inﬂuence of adipokines on articular cartilage varies as different
stages of the OA process. We did not assess body composition,
which is important as BMI does not discriminate adipose from non-
adipose body mass, and evidence suggests fat and muscle
contribute opposite effects to the pathogenesis of OA47. A further
limitation was the potential impact of confounding medical con-
ditions, such as insulin resistance state and dyslipidemia, or med-
ications used, which was not assessed for in the current study. The
association of leptin-to-adiponectin ratio, a possible surrogate
marker of insulin resistance48, with cartilage outcomes was not
statistically signiﬁcant. Blood and urine for adipokine andbiomarker analysis were not taken in the fasted state; this has been
shown to affect markers of bone resorption49. We did not stan-
dardize time of day collection; instead, subjects were assessed at
the time of their MRI, given accessibility. Markers of cartilage
turnover exhibit diurnal variation, although the postulated mech-
anism is physical activity e the biomarkers accumulate in the
synovium of osteoarthritic joints during rest and are transported
via the lymphatics to the circulation during activity50. As the
original study also assessed delayed gadolinium-enhanced MRI of
cartilage (dGEMRIC), all of our subjects were required to ambulate
prior to MRI making this less likely to be a factor.
Overall, our study has demonstrated that weight loss is associ-
ated with increases in adiponectin and decreases in leptin; these
changes in turn were associated with both reduced knee cartilage
volume and thickness loss, These relationships were not indepen-
dent of weight loss itself, suggesting that mechanical loading is the
driving etiology of cartilage changes. Nonetheless, this suggests a
possible additional mechanism for reduced cartilage loss in obese
people who lose weight, as identiﬁed in our recent study32. The
association between COMP and cartilage volume and thickness loss
indicates it may be a useful joint biomarker.
Determining the metabolic mechanisms of obesity-related joint
changes offers another potential approach towards the goal of
disease-modifying therapy in OA, through the development of
therapeutic strategies to counteract dysregulation of pro-
inﬂammatory adipokine production and downstream events.
Further work is required to determine the relative contributions of
metabolic and mechanical factors in the pathogenesis of knee OA,
and to explore additional parameters of metabolic change
including insulin resistance.
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